title: Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.
abstract: BACKGROUND
  There are no data on the patterns of care and outcome of very elderly patients with castration-resistant prostate cancer (CRPC) treated with docetaxel.
  
  
  OBJECTIVE
  To assess the routine use of first-line docetaxel-based chemotherapy in CRPC patients aged >75 yr.
  
  
  METHODS
  We reviewed the clinical files of 175 patients aged > or =75 yr with CRPC treated with first-line docetaxel in nine French tertiary care cancer centres from 2000 to 2007.
  
  
  METHODS
  Response rate, survival, and adverse events (AE).
  
  
  CONCLUSIONS
  Median age was 78 yr. Ninety-five patients (54%) received a standard 3-wk regimen (SR), and 80 patients (46%) received an adapted regimen (AR) delivered on a weekly schedule with various times for rest periods. Patients treated with an AR were older (>80 yr) and had poorer performance status (PS; > or =2) than patients treated with the SR. The prostate-specific antigen (PSA) response rates were not significantly different between the standard and adapted treatment groups (71% vs 68%, p=0.79). The median progression-free survival (PFS) was 7.4 mo. The median overall survival (OS) was 15 mo. The incidence of grade 3 or 4 AEs was 46% and was correlated with poor PS and the presence of visceral disease but not with the regimen. Early discontinuation of treatment because of toxicity occurred more frequently in the AR group than in the SR group (30% vs 8.4%, p=0.0005). In multivariate analysis, only PS and the presence of visceral disease were predictors of OS.
  
  
  CONCLUSIONS
  Docetaxel is active and feasible in elderly patients with good PS. The optimal treatment of frail patients with CRPC remains to be established. Geriatric tools should be used to more accurately detect elderly CRPC patients who are unfit for chemotherapy. Age by itself should not be used as a criterion to deny patients with CRPC a potentially effective chemotherapy.
authors.affiliation: Department of Medicine, Institut Gustave Roussy, Villejuif, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Italiano
authors.forename: Cécile
authors.initials: C
authors.lastname: Ortholan
authors.forename: Stéphane
authors.initials: S
authors.lastname: Oudard
authors.forename: Damien
authors.initials: D
authors.lastname: Pouessel
authors.forename: Gwenaëlle
authors.initials: G
authors.lastname: Gravis
authors.forename: Philippe
authors.initials: P
authors.lastname: Beuzeboc
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Bompas
authors.forename: Aude
authors.initials: A
authors.lastname: Fléchon
authors.forename: Florence
authors.initials: F
authors.lastname: Joly
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Ferrero
authors.forename: Karim
authors.initials: K
authors.lastname: Fizazi
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects; D015331:Cohort Studies; D018572:Disease-Free Survival; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D015577:Geriatric Assessment; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D043823:Taxoids; D000077143:Docetaxel; D017430:Prostate-Specific Antigen